Abbott faces trial over claims that preterm infant formula caused dangerous disease

Similac baby formula maker Abbott (ABT.N) is expected to face a trial on Monday over claims that its formula for preterm infants used in neonatal intensive care units causes a potentially deadly bowel disease, the second trial out of hundreds of similar lawsuits in the United States.